ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Capricor Therapeutics, Inc. ã¯ãå¹
åºãçŸæ£ã®æ²»çãšäºé²ã®ããã®é©æ°çãªçްèããã³ãšã¯ãœãœãŒã ããŒã¹ã®æ²»çè¬ã®éçºã«æ³šåããŠããŸããå瀟ã®äž»ååè£ã§ããåçš®å¿èç±æ¥çްèçæ³ã® CAP-1002 ã¯ãæ«æãã¥ã·ã§ã³ãåçãžã¹ãããã£ãŒ (DMD) æ£è
ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšãå®äºããŠããŸãããŸããCOVID-19 ã«é¢é£ãããµã€ãã«ã€ã³ ã¹ããŒã ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšäžã® CAP-1002 ã¯ãå¿äžå
šãå¿æ©èœäžå
šã䌎ãå¿çæ¢å¡åŸãªã©ã®å¿èçŸæ£ã®æ²»çãç®çãšãã CAP-1002 ã®äœ¿çšã調æ»ããããŸããŸãªè©Šéšãå®äºããŠããŸãããŸããå€å·é¢é£ã®å·å®³ãçŸæ£ã®æ²»çãç®çãšããåèšåºéçºæ®µéã® CAP-2003 ãšãCOVID-19 ã®æœåšçãªäºé²ãç®çãšããåèšåºæ®µéã® 2 ã€ã®ã¯ã¯ãã³åè£ãéçºäžã§ãã Capricor ã¯ãDMD ããã³ãã®ä»ã®é©å¿çã®æ²»çã®ããã®çްèçæ³åè£ã§ãã CAP-1002 ã®éçºã§ Lonza Houston, Inc. ãšææºããŠããŸããå瀟㯠2005 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãããªãŒãã«ãºã«æ¬ç€Ÿã眮ããŠããŸãã